Document is current
Any future updates will be listed below
-
Authors
Hannani, Monica T.
Bacardit, Jaume
Larkin, Jonathan
Glumoff, Virpi
Karsdal, Morten A.
Bay-Jensen, Anne-Christine
Mobasheri, Ali
Thudium, Christian S.
-
Funding
Funding for this research was provided by:
Copenhagen University
- License Information
-
More Information
Article History
Received: 22 September 2025
Accepted: 13 January 2026
First Online: 27 January 2026
Declarations
:
: This study involved human participants and complied with the protocol, Good Clinical Practice, the Declaration of Helsinki, and the ethical and legal regulatory requirements for France (2017-A02469-44), The Netherlands (NL61405.041.17), Norway (2017 − 1051), and Spain (2015 − 651).
: All study participants provided written informed consent to participate in the study before taking part.
: MTH, MAK, ACBJ, and CST are full-time employees and shareholders of Nordic Bioscience A/S. JL is the founder of SynOA Therapeutics. AM has provided consultancy for Genacol, Sterifarma, Sanofi (Brazil), Janssen-Cilag (Brazil), Sanofi (France), Sanofi (USA), Pacira Biosciences, Grünenthal, Viatris, Novartis, Expanscience, Galapagos, Chiron, Dorian Therapeutics, Kolon TissueGene, Ampio Pharmaceuticals, Aptissen SA, Contura, HALEON, Nestlé, Nestlé Wobenzym, Synartro AB, Pfizer Consumer Healthcare, GSK Consumer Healthcare, and Aché (Aché Laboratórios Farmacêuticos). JB and VG declare no competing interests.
